Chris Ryan

Findings from a meta analysis showed that JAK inhibitors were associated with improved outcomes vs best available therapy in myelofibrosis.

Komal Jhaveri, MD, FACP, discusses management strategies for ocular toxicities and other ADC-related adverse effects in breast cancer.

Rebecca Dent, MD, MSc, discusses data from the TROPION-Breast02 trial evaluating first-line Dato-Dxd in immunotherapy-ineligible triple-negative breast cancer

The FDA granted orphan drug designation to DPTX3186 in gastric cancer.

The FDA granted orphan drug designation to an exosome-based therapy for glioblastoma multiforme.

Vepugratinib-based treatment was safe and active in FGFR3-altered metastatic urothelial cancer.

The European Commission approved perioperative pembrolizumab plus adjuvant radiotherapy with or without cisplatin in resectable locally advanced HNSCC.

PlasmaSure received FDA breakthrough device designation for low- to intermediate-risk non–muscle-invasive bladder cancer.

EVX-01 plus pembrolizumab generated an overall response rate of 75% and durable T-cell responses in advanced melanoma.

WES-aneuploidy scores may identify patients with dMMR endometrial cancer who do not benefit from the addition of immunotherapy to chemotherapy.

A data safety monitoring board recommended the continuation of a study of Bria-IMT plus immune checkpoint inhibition in metastatic breast cancer.

Adjuvant atezolizumab improved DFS and OS in patients with muscle-invasive bladder cancer who tested positive for ctDNA after radical cystectomy.

Will the FDA approve a resubmitted biologics license application for RP1 plus nivolumab in advanced melanoma after progression on anti–PD-1 therapy?

Lutetium Lu 177 vipivotide tetraxetan plus an ARPI and ADT improved rPFS in metastatic hormone-sensitive prostate cancer.

Neoadjuvant T-DXd followed by THP improved pathological complete response rate in high-risk, HER2-positive early-stage breast cancer.

Long-term data demonstrated durable responses with pimicotinib in tenosynovial giant cell tumor.

Osimertinib plus chemotherapy improved OS vs osimertinib alone in EGFR-mutated advanced non–small lung cancer, irrespective of poor prognostic factors.

The EMA’s CHMP has recommended the approval of asciminib for Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase.

Pembrolizumab plus chemotherapy with or without bevacizumab improved overall survival in platinum-resistant ovarian cancer.

A study found ChatGPT 3.5 was more likely to give incomplete or inaccurate answers to specific hematologic malignancy queries vs general questions.

Toripalimab plus CCRT produced a 100% ORR in locally advanced cervical cancer, although the regimen was associated with radiation-related AEs and irAEs.

Joseph Jacob, MD, MCR, discusses the significance of the FDA approval of TAR-200 for BCG-unresponsive non–muscle-invasive bladder cancer.

The FDA granted breakthrough therapy designation to ficerafusp alfa plus pembrolizumab for metastatic/recurrent head and neck squamous cell carcinoma.

The FDA granted breakthrough therapy designation to sonrotoclax for relapsed/refractory mantle cell lymphoma.

The removal of REMS programs for approved CAR T-cell therapies could enable improved access and streamlined management of hematologic malignancies.

OST-HER2 produced a potential overall survival benefit at 2 years in recurrent, fully resected, pulmonary metastatic osteosarcoma.

Daratumumab plus lenalidomide, with reduced exposure to dexamethasone, led to a PFS improvement in frail, newly diagnosed multiple myeloma.

The FDA granted fast track designation to ADCE-D01 for the treatment of soft tissue sarcoma.

The FDA approved cemiplimab-rwlc for the adjuvant treatment of cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation.

The FDA granted priority review to a biologics license applications seeking the approval of Orca-T for select hematologic malignancies.